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Background: Certain adenovirus serotypes cause severe infections, especially in children. It is important to monitor
temporal changes in serotypes causing clinical disease. The objective of this study was to document circulating
respiratory adenovirus serotypes by sequencing adenovirus culture isolates from the Greater Toronto Area, Ontario,
during December 2008 to April 2010.
Methods: Nucleic acid extraction was performed on 90 respiratory tract adenovirus culture isolates. PCR
amplification was conducted with primers targeting the adenovirus hexon gene hypervariable region 7. Sanger
sequencing and phylogenetic analyses were performed to determine serotype identities.
Results: Among 90 clinical respiratory isolates sequenced, eight different serotypes were identified. Serotype 3 (34,
38%), serotype 2 (30, 30%), and serotype 1 (14, 16%) isolates were most common; serotypes 5, 6, 11, 17 and 21
were also observed. Seventeen (50%) of the 34 HAdV-3 isolates were identified between December 2008 and
February 2009, while none were identified from December 2009 to February 2010. Between December 2008 and
April 2009, the two most common serotypes were HAdV-3 and HAdV-2, detected in 18 (53%) and 8 (24%) of the 34
cultures isolates, respectively. However, from December 2009 to April 2010, there was an increase in HAdV-2, which
became the most prevalent serotype, detected in 10 (50%) of the 20 isolates identified (p = 0.05).
Conclusions: There was a gradual shift in prevailing adenovirus serotypes during the 17 month study period, from
predominantly HAdV-3 to HAdV-2. If an adenovirus vaccine were to be broadly implemented, multiple serotypes
should be included.
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Human adenovirus (HAdV) belong to the Adenoviridae
family and the Mastadenovirus genus [1]. They are struc-
turally icosahedral, non-enveloped, double-stranded, lin-
ear DNA viruses [1]. HAdV are responsible for causing a
variety of diseases including upper and lower respiratory
infections, conjunctivitis, pneumonia, gastroenteritis and
hemorrhagic cystitis [2]. More severe disease is observed
among children, the elderly and immunocompromised
persons [2,3]. Transmission of HAdV can occur by direct* Correspondence: jonathan.gubbay@oahpp.ca
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reproduction in any medium, provided the orcontact, small droplet aerosols, through the water system,
and via the fecal-oral route [1,4].
Currently there are 52 known HAdV serotypes, each
classified into one of the seven different species ranging
from A to G, based on immunological and biochemical
characteristics [1]. Respiratory tract infections are caused
by serotypes in species B, C and E [1]. There are 10
HAdV serotypes that have been associated with pneu-
monia and febrile respiratory illness (FRI) [5]. However,
only HAdV-3, HAdV-4, HAdV-7 and HAdV-21 have
been found to cause outbreaks of both FRI and acute re-
spiratory disease (ARD) [5,6]. Determining prevailing
serotypes in a community assists in better understandingLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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types in order to control its spread.
A recent study undertaken at Public Health Ontario
Laboratories (PHOL) described adenovirus serotypes cir-
culating in the Greater Toronto Area (GTA), Ontario
from September 2007 to June 2008. The predominant
serotypes observed were HAdV-3 (46%), HAdV-2 (26%),
HAdV-1 (18%) and HAdV-21 (5%); HAdV-14 was not
documented [3]. The current study was conducted to
document whether circulating adenovirus serotypes change
temporally within the same geographic area, and to what
degree these changes have occurred between December
2008 and April 2010 in the GTA of Ontario.
Methods
Sample source and study isolates
PHOL performs a large proportion of primary respira-
tory viral testing for the province of Ontario from a var-
iety of clinical settings including ambulatory, hospital
and outbreaks. Following the testing procedure for re-
spiratory specimens, nasopharyngeal swabs (NPS) from
ambulatory and hospitalized, non-intensive care unit
(non-ICU) patients received by PHOL-Toronto are cul-
tured for virus isolation in two cell lines. One line is
monkey kidney cells [either Rhesus (RMK) or African
green monkey kidney cells (AGMK)], and the other is
WI-38 human embryonic lung fibroblast cells (Diagnostic
Hybrids, Inc. Athens, Ohio, USA). Cell lines showing cyto-
pathic effect are stained with a blend of murine monoclo-
nal antibodies (MAbs) directed against seven respiratory
viruses plus separate DFA reagents, each consisting of
MAb blends directed against a single respiratory virus, in-
cluding adenovirus (D3 Ultra™ DFA Respiratory Virus
Screening & ID Kit, Diagnostics Hybrids). Samples sub-
mitted from patients in outbreak or ICU settings undergo
multiplex molecular testing for respiratory viruses, and
only a proportion also have viral culture done.
All available adenovirus culture isolates, identified
from December 2008 to April 2010 at PHOL, were
selected for this study. Samples that underwent molecu-
lar testing, but not viral culture, were not included. The
period from December until April was regarded as
winter/early spring. Isolates were derived from persons
ranging in age from newborns to adults (0–88 years),
with 73 (81%) from persons under 18 years of age, and
17 (19%) from persons 18 years of age or older.
This study was considered exempt from University of
Toronto’s Health Sciences Research Ethics Board review
as it involved deidentified respiratory tract samples that
were tested as part of a clinical virology service provided
by PHOL. All test-positive samples and a proportion of
test negative samples are stored for possible further
laboratory-based surveillance work. Samples and isolates
included in this study were analyzed as part of theroutine respiratory viral molecular surveillance program
that supports Ontario’s Ministry of Health and Long-
Term Care.
Molecular serotyping
The methods closely follow those developed by Yeung et al.
[3]. From each tissue culture isolate, a 250 μL aliquot under-
went total nucleic acid extraction using the bioMérieux
NucliSENSW easyMAGW protocol (bioMérieux Inc. Marcy
I’Etoile, Rhone, France); a total elution volume of 55 μL per
isolate was obtained.
The primers used for the polymerase chain reaction
(PCR) were taken from Sarantis et al., targeting the
highly conserved regions flanking the hypervariable
region-7 (HVR-7) of the HAdV hexon gene [2]. These
primers generated amplicons ranging from 605 to 629
base pairs from known adenovirus serotypes [2]. For
each reaction there was a total volume of 45 μL, com-
posed of 5 μL of forward primer, 5 μL of reverse primer,
20 μL of the QiagenW Quantitect Multiplex Master Mix
(Qiagen, Inc. Venlo, Limburg, Netherlands), 10 μL of
RNase free water and 5 μL of DNA template. PCR was
performed on the Bio-Rad iCycler iQ™ Real-Time PCR
Detection System (Bio-Rad Laboratories, Inc. Hercules,
CA, USA). PCR reaction started with 3 min of initial de-
naturation step at 94°C, and proceeded with 34 cycles of
denaturation for 1 min at 94°C, annealing for 1 min at 60°
C and elongation for 1 min at 72°C. This was followed by
a final 10 min incubation step at 72°C. Five microliters of
the PCR product was then mixed with 1 μL of 6X Fer-
mentasW loading dye and loaded on to a 1% agarose gel
with ethidium bromide along with a FermentasW GeneRu-
ler™ 100 base pair (bp) DNA ladder (Thermo Fisher Scien-
tific, Waltham, MA, USA). The gel was run for 30 min at
120 volts using a Bio-Rad PowerPac Basic™ Power Supply,
and Bio-Rad Molecular ImagerW Gel Doc™ XR+ Im-
aging System was used to visualize the band of nucleic
acid at the 600 bp mark.
BigDye™ Terminator Sequencing Kit (Applied Biosystems,
Inc. Foster City, CA, USA) was used to label the DNA. Two
reactions per sample were conducted, one with the forward
primer and the second with the reverse primer. Each reac-
tion had a total volume of 20 μL, with 2 μL of BigDye™ ter-
minator ready mix, 3 μL of 5x Sequencing Buffer, 2 μL of
forward/reverse primers, 8 μL of RNase free water and 5 μL
of PCR product. The amplification parameters for the Big-
Dye™ PCR were as follows: the initial denaturation step was
1 min at 96°C, followed by 25 cycles of 10 second denatur-
ation at 96°C, 5 seconds of annealing at 55°C and 4 min of
elongation at 60°C.
The excess BigDye™ Terminator components were
cleaned using the QiagenW DyeEx 2.0 Spin Kit protocol.
The liquid end product was dried and re-suspended with
Applied Biosystems Hi-Di™ formamide and loaded onto
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obtained were analyzed using FinchTV™ (Geospiza, Inc.
Seattle, WA, USA), and each serotype was designated
using NCBI BLAST scores. Isolates with a match in
GenBank with 98% or greater Max Identity score were
categorized as belonging to the same serotype [2].
Raw data was entered into an Excel 2010 spreadsheet
(Microsoft Co. Redmond, WA, USA) and subsequently
analyzed using IBMW SPSSW Statistics 20 (International
Business Machines Co. Armonk, NY, USA). Proportions
were compared by χ2 test; all hypothesis tests were two-
tailed, and p <0.05 was considered significant.
Phylogenetic analysis
HAdV species specific phylogenetic trees were con-
structed using the maximum likelihood method. Statis-
tical significance of the tree topology was tested by
bootstrapping (1,000 replicates) using MEGA 5.05 soft-
ware [7]. Evolutionary distances were derived using the
Kimura-2 parameter method [8]. GTA HAdV nucleotide
sequences and the corresponding reference sequences
were included in the phylogenetic analysis after multiple
alignments using the ClustalW algorithm.
Nucleotide sequence accession numbers
The HAdV sequences that are reported here were all
deposited onto the GenBank sequence database with ac-
cession numbers JX901190 to JX901279.
Results
HAdV serotype identity and distribution
Between December 2008 and April 2010, HAdV was
detected in 229 (0.9%) of the 24,406 respiratory samples
processed at PHOL-Toronto by culture and/or molecu-
lar testing; 90 (44%) of the 207 documented culture iso-
lates were still in storage and of sufficient volume
(250 μL) to be sequenced. Table 1 shows the distribution
of serotypes identified during the course of this study.Table 1 Serotype identities and sex and age distribution of so
culture isolates identified in the Greater Toronto Area, Ontar




B 3 34 (38%) 18
11 2 (2%) 2
21 6 (7%) 5
C 1 14 (16%) 5
2 30 (33%) 14
5 2 (2%) 0
6 1 (1%) 1
D 17 1 (1%) 0
Total 45 (50%)Our findings indicate that the most prevalent serotypes
were HAdV-3 and HAdV-2, followed by HAdV-1. We
also detected serotypes HAdV-5, HAdV-6, HAdV-11,
HAdV-17 and HAdV-21. Males and females were equally
represented. Significantly more (56, 62%) isolates were
from children ≤ 4 years of age than from persons > 4 years
of age (34, 38%; p <0.001). HAdV-1 was only observed in
children ≤ 4 years of age, and HAdV-2 was also signifi-
cantly more common in this age group (p <0.001; see
Table 1). Among the 17 isolates detected throughout the
study period from persons aged ≥ 18 years, the serotypes
detected include HAdV-3 and HAdV-21 (6, 35% each),
HAdV-2 and HAdV-11 (2, 12% each), and HAdV-17
(1, 6%). HAdV-11, HAdV-17 and HAdV-21 were not
detected in children [(age < 18 years); see Table 1].
Geographical distribution
Figure 1 illustrates the geographic distribution of the dif-
ferent HAdV serotypes across the GTA. The majority of
the HAdV cases that occurred from December 2008 to
April 2010 were in the cities of Toronto (38, 42%),
Brampton and Mississauga (18, 20% each). They were
also the three most common cities of origin among all
229 HAdV positive samples tested at PHOL. Toronto
(109, 48%) and Mississauga (48, 21%) contributed similar
proportions of cases, but Brampton (27, 12%) had less
when compared to the subset of 90 sequenced isolates.
Also, Figure 1 shows that HAdV-3 and HAdV-2 were
widely distributed throughout the GTA, while the three
serotypes that were detected only in adults, HAdV-21,
HAdV-17 and HAdV-11, were each restricted to a single
city. HAdV-21 and HAdV-17 were only identified in Toronto,
and HAdV-11 was only found in Brampton.
Temporal distribution
Figure 2 demonstrates the temporal changes in HAdV
serotypes over the course of the 17 month study period.
Between December 2008 and April 2009, the two mosturce patients of 90 human adenovirus respiratory
io, from December 2008 to April 2010
Age
F ≤ 4 4 < to < 18 ≥ 18
16 17 (50%) 11 (32%) 6 (18%)
0 0 0 2
1 0 0 6 (100%)
9 14 (100%) 0 0
16 22 (73%) 6 (20%) 2 (7%)
2 2 0 0
0 1 0 0
1 0 0 1
45 (50%) 56 (62%) 17 (19%) 17 (19%)
Figure 1 Geographical distribution of human adenovirus serotypes causing respiratory infection in the Greater Toronto Area, Ontario,
from December 2008 to April 2010. Pie charts represent the HAdV serotypes identified in each region, and their subsequent serotypic
identities. The numbers within the pie charts are percentages from the total of each serotype. The “N” number above each chart represents the
total number of samples that were found in that area.
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in 18 (53%) and 8 (24%) of the 34 cultures isolates, re-
spectively. However, from December 2009 to April 2010,
there was an increase in HAdV-2, which became the most
prevalent serotype, detected in 10 (50%) of the 20 isolates
identified (p =0.05). Also, of the total 34 HAdV-3 isolates
identified, 17 (50%) were found between December 2008
and February 2009, while none were detected between
December 2009 and February 2010 (p <0.001). In addition,
during December 2008 to February 2009, 6 (21%) of the
29 isolates were HAdV 2. However, between December
2009 and February 2010, 5 (56%) of the 9 isolates identi-
fied during that time period were HAdV-2 (p <0.05).
Thus, HAdV-2 was observed to be prevalent throughout
the study period, whereas HAdV-3 was observed inten-
sively from December 2008 to August 2009, and its fre-
quency diminished with time.
Phylogenetic analysis
For the phylogenetic analysis, hexon gene sequences
(ranging from 503 to 599 nucleotides) of the GTA
HAdV isolates included in this study, along with refer-
ence sequences of HAdV species and serotypes were
analyzed. Serotype identity was determined based onnucleotide similarity of ≥ 98% compared to respective
reference sequences, all of which were included in the
phylogenetic tree (Figure 3). Intraserotypic nucleotide
sequence identities varied for different serotypes when
comparing our study isolates to each other, with a range
of 95–99%. Sequence identities for HAdV-1 (97–100%),
HAdV-2 (95–99%), HAdV-3 (97–99%), and HAdV-21
(97–99%), varied. HAdV-5 and HAdV-11 showed iden-
tities of 97% and 99.3%, respectively among the 2 isolates
belonging to each serotype. Intraserotypic sequence
identities were not available for HAdV-6 and HAdV-17,
as only one isolate belonged to each serotype.
Discussion
We have observed a significant change in the circulat-
ing HAdV serotypes in the GTA of Ontario during
December 2008 to April 2010. Of note is a significant
decline in HAdV-3 and an increase in HAdV-2 in the
population during the study period. These findings
demonstrate that multiple serotypes would need to be
included in order to create an effective HAdV vac-
cine. PHOL-Toronto is responsible for testing most,
but not all cases of HAdV in the GTA; there are other
tertiary institutions that test their own samples, and
Figure 2 Temporal distribution of human adenovirus serotypes causing respiratory infection in the Greater Toronto Area, Ontario,
from December 2008 to April 2010.
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fully representative of all of the GTA’s HAdV cases. In
addition, the generalizability of this study was further
limited due to the fact that we were only able to se-
quence 90 (39%) of the 229 HAdV isolates that were
detected at PHOL-Toronto during the study period,
since only samples that were tested by viral culture
were included. PHOL does not perform culture on
samples from outbreaks or ICU patients, as these are
tested by multiplex molecular methods. Thus, our
sample was biased towards patients with less severe
infections.
Yeung et al. showed that the prevalent serotypes in
Ontario from September 2007 till June 2008 were
HAdV-3 (44, 46%), HAdV-2 (25, 26%), HAdV-1 (17,
18%) and HAdV-21 (5, 5%) [3]. Our study demonstrates
a similar serotype distribution with HAdV-3 (34, 38%),
HAdV-2 (30, 33%), HAdV-1 (14, 16%) and HAdV-21 (6, 7%)
also being most prevalent. We also documented a significant
decline in HAdV-3 infections in the final 4 months of the
study, suggesting a change in serotype distribution. Chen
et al. also documented a marked shift in circulating sero-
types in consecutive seasons in hospitalized children in
southern Taiwan between 2001 and 2002 [9]. In 2001,
HAdV-4 was found in the majority (57%) of isolates, while
HAdV-3 was rare (5%) [9]. In 2002, while HAdV-3 became
the major type (46%), the previously predominant HAdV-4
decreased to 6 per cent, and HAdV-7 increased from 2 to 19
per cent [9].
The cause for this seasonal change in serotype is yet
unknown. One hypothesis could be due to unknown en-
vironmental factors, such as humidity and temperature.
Another could be possible favourable or unfavourableinteractions with other circulating respiratory viruses. It
may also be that a build-up of immunity in the population
could contribute to the decline in a serotype; in contrast,
waning population level immunity to certain serotypes
may result in an increase in prevalence/incidence.
As we observed, the previous study at this laboratory
showed that the majority, 70 (73%) of the 96 isolates,
were from children ≤ 4 years of age [3]. These findings
are consistent with other studies that have also shown
that pediatric populations with acute respiratory diseases
are commonly infected with HAdV-1, HAdV-2, or
HAdV-3 [10]. Furthermore, the literature also demon-
strates that most adult populations with HAdV infections
are predominantly infected with HAdV-3, HAdV-4,
HAdV-7 and HAdV-11, with a few HAdV-1, HAdV-2,
HAdV-6 and HAdV-14 cases [11]. Of note in this
study, HAdV-11, HAdV-17 and HAdV-21 were only
found among the adult population (age ≥ 18 years).
Adenovirus respiratory infections are highly prevalent
in children; they have been documented in 5 to 11% of
upper respiratory tract infections and bronchitis, 4 to
10% of pneumonia and pharyngitis, 2 to 10% of bron-
chiolitis, and 3 to 9% of croup in children [6]. Most out-
breaks of adenovirus respiratory infections, especially in
children < 7 years of age, have been caused by HAdV-3,
HAdV-4, HAdV-7 and HAdV-21 [6]. Notably two of
these serotypes, namely HAdV-3 and HAdV-21, have
been circulating in the GTA for the past few years, as
observed in this study and by Yeung et al [3].
From 1971 until 1996 the United States (US) had live
oral adenovirus vaccines against HAdV-4 and HAdV-7
available for members of the military [12]. The vaccines
were effective in preventing adenovirus infections; in
Figure 3 Phylogenetic trees of Greater Toronto Area human adenovirus species B, C and D hexon gene, hypervariable region 7 (HVR
7), nucleotide sequences. (a). HAdV B species and corresponding serotypes (3, 11, 21), (b). HAdV C species and corresponding serotypes (1, 2, 5,
6), and (c). HAdV D species and corresponding serotype (17). Reference sequences representing known serotypes are indicated by a solid circle.
Multiple sequences alignments and phylogenetic trees were constructed using ClustalW and the maximum likelihood method algorithm within
MEGA 5.05 software, respectively. Tree topology was supported by bootstrap analysis with 1000 pseudo replicate datasets. The scale bar
represents the number of nucleotide substitutions per site between close relatives.
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among military recruits [12]. Studies conducted on the
serum of vaccinated recruits have demonstrated a small
cross-protective effect of the HAdV-4 and HAdV-7 vac-
cines against HAdV-3 and HAdV-14 [12,13]. Following
the withdrawal of the adenovirus vaccination program,
there was an outbreak of HAdV-14 in US military train-
ing camps in 2006 [12]. HAdV-14 had never been
observed in a US recruit before 2006 [13,14]. These out-
breaks have sparked recognition of the importance of
continued adenovirus surveillance as well as a need for a
vaccine [14]. In fact, due to a reoccurrence of HAdV
outbreaks among military personnel, a second gener-
ation live oral vaccine against HAdV-4 and HAdV-7 was
approved by the US Food and Drug Administration
(FDA) in March 2011 [15]. As of October 2011, this vac-
cine is being administered to US military recruits [15].
Our findings suggest that for the development of a
new vaccine, more serotypes would have to be included,
since the prevalence of HAdV serotypes may change.
The rapid shift in serotypes from season to season sug-
gests that a more successful vaccine will be serotype in-
dependent, and directed against common epitopes
shared by all serotypes. Continued molecular epidemio-
logical surveillance of circulating adenovirus serotypes is
a critical tool in monitoring the changes in HAdV sero-
types causing clinical disease.
Conclusions
There was a gradual shift in prevailing adenovirus sero-
types during the 17 month study period, from predom-
inantly HAdV 3 to HAdV 2. If an adenovirus vaccine
were to be broadly implemented, multiple serotypes
should be included.
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